These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 31056428)
1. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428 [TBL] [Abstract][Full Text] [Related]
2. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation. Vidal AF; Ferraz RS; El-Husny A; Silva CS; Vinasco-Sandoval T; Magalhães L; Raiol-Moraes M; Barra WF; Pereira CLBL; de Assumpção PP; de Brito LM; Vialle RA; Santos S; Ribeiro-Dos-Santos Â; Ribeiro-Dos-Santos AM BMC Cancer; 2021 Apr; 21(1):363. PubMed ID: 33827469 [TBL] [Abstract][Full Text] [Related]
4. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
6. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
7. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Coffee B; Cox HC; Kidd J; Sizemore S; Brown K; Manley S; Mancini-DiNardo D Cancer Genet; 2017 Feb; 211():5-8. PubMed ID: 28279308 [TBL] [Abstract][Full Text] [Related]
8. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
9. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
10. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246 [TBL] [Abstract][Full Text] [Related]
11. Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated ( Hall MJ; Bernhisel R; Hughes E; Larson K; Rosenthal ET; Singh NA; Lancaster JM; Kurian AW Cancer Prev Res (Phila); 2021 Apr; 14(4):433-440. PubMed ID: 33509806 [TBL] [Abstract][Full Text] [Related]
16. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767 [TBL] [Abstract][Full Text] [Related]
18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
19. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044 [TBL] [Abstract][Full Text] [Related]
20. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]